<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:mp ids='MP_0001198'>Tight skin</z:mp> (Tsk) mutation is a duplication of the mouse fibrillin 1 (Fbn1) gene that results in a larger (418 kD) than <z:mpath ids='MPATH_458'>normal</z:mpath> (350 kD) protein; Tsk/+ mice display <z:hpo ids='HP_0009025'>increased connective tissue</z:hpo>, bone <z:hpo ids='HP_0001548'>overgrowth</z:hpo>, and lung <z:hpo ids='HP_0002097'>emphysema</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Lung <z:hpo ids='HP_0002097'>emphysema</z:hpo>, bone <z:hpo ids='HP_0001548'>overgrowth</z:hpo>, and vascular complications are the distinctive traits of mice with reduced Fbn1 gene expression and of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) patients with heterozygous fibrillin 1 mutations </plain></SENT>
<SENT sid="2" pm="."><plain>Although Tsk/+ mice produce equal amounts of the 418- and 350-kD proteins, they exhibit a relatively mild phenotype without the vascular complications that are associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> patients and fibrillin 1-deficient mice </plain></SENT>
<SENT sid="3" pm="."><plain>We have used genetic crosses, cell culture assays and Tsk-specific antibodies to reconcile this discrepancy and gain new insights into microfibril assembly </plain></SENT>
<SENT sid="4" pm="."><plain>Mice compound heterozygous for the Tsk mutation and hypomorphic Fbn1 alleles displayed both Tsk and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> traits </plain></SENT>
<SENT sid="5" pm="."><plain>Analyses of immunoreactive fibrillin 1 microfibrils using Tsk- and species-specific antibodies revealed that the mutant cell cultures elaborate a less abundant and morphologically different meshwork than control cells </plain></SENT>
<SENT sid="6" pm="."><plain>Cocultures of Tsk/Tsk fibroblasts and human WISH cells that do not assemble fibrillin 1 microfibrils, demonstrated that Tsk fibrillin 1 copolymerizes with <z:mp ids='MP_0002169'>wild-type</z:mp> fibrillin 1 </plain></SENT>
<SENT sid="7" pm="."><plain>Additionally, copolymerization of Tsk fibrillin 1 with <z:mp ids='MP_0002169'>wild-type</z:mp> fibrillin 1 rescues the abnormal <z:mp ids='MP_0000002'>morphology</z:mp> of the Tsk/Tsk aggregates </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, the studies suggest that bone and lung abnormalities of Tsk/+ mice are due to copolymerization of mutant and <z:mp ids='MP_0002169'>wild-type</z:mp> molecules into functionally deficient microfibrils </plain></SENT>
<SENT sid="9" pm="."><plain>However, vascular complications are not present in these animals because the level of functional microfibrils does not drop below the critical threshold </plain></SENT>
<SENT sid="10" pm="."><plain>Indirect in vitro evidence suggests that a potential mechanism for the dominant negative effects of incorporating Tsk fibrillin 1 into microfibrils is increased proteolytic susceptibility conferred by the duplicated Tsk region </plain></SENT>
</text></document>